The Clorox Company (CLX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 May, 2026Executive summary
Q3 net sales were $1.67 billion, flat year-over-year, with mixed results and slower-than-expected improvement in some businesses; nine-month sales declined 7% due to lower shipments post-ERP transition.
ERP implementation and digital transformation are now complete, stabilizing operations and setting a foundation for future growth.
Innovation and market share gains continue in key segments, but progress is uneven, especially in Litter and Food.
The GOJO (Purell) acquisition was completed April 1, 2026, for $2,250 million, financed with new credit facilities and commercial paper.
Diluted EPS rose 3% to $1.54 for the quarter, while adjusted EPS increased 13% to $1.64, but nine-month EPS fell 10% due to higher costs and lapping prior-year insurance recoveries.
Financial highlights
Gross margin for Q3 was 43.2%, down 140 basis points year-over-year, mainly from higher supply chain and manufacturing costs and unfavorable mix.
Net earnings attributable to shareholders were $187 million for the quarter; operating cash flow for nine months was $282 million, down from $687 million, mainly due to a $476 million Glad JV payment.
Segment adjusted EBIT for Q3 was $296 million, up from $266 million, but for nine months was $712 million, down from $856 million.
GOJO acquisition adds $200 million in Q4 revenue, about 10% for the quarter and 3% for the full year.
Selling and administrative expenses and advertising costs both decreased as a percentage of sales, reflecting lower digital transformation and incentive compensation costs.
Outlook and guidance
FY2026 net sales expected to decline about 6%, including nearly 3 points of positive impact from GOJO; organic sales expected to decrease about 9% due to ERP-related shipment headwinds.
Gross margin projected to decline 250–300 basis points, with 60 basis points of headwinds from GOJO acquisition.
FY2026 diluted EPS forecasted at $4.78–$4.98 (down 24–27% YoY); adjusted EPS at $5.45–$5.65 (down 27–29%).
Cost inflation, especially from oil, remains a key uncertainty for fiscal 2027; mitigation will rely on cost savings, pricing, and productivity.
Guidance for 2027 will be provided in August, with ongoing scenario planning for various cost environments.
Latest events from The Clorox Company
- Digital transformation and IGNITE strategy accelerate growth, margin expansion, and innovation.CLX
Consumer Analyst Group of New York Conference 20259 Jul 2026 - Net sales fell 19% and gross margin dropped to 41.7% amid ERP transition impacts.CLX
Q1 20269 Jul 2026 - $2.25B acquisition expands health & hygiene leadership, driving $50M in synergies.CLX
M&A announcement9 Jul 2026 - Q2 FY2026 sales and earnings declined, with major acquisitions and ongoing cost pressures.CLX
Q2 20268 Jul 2026 - FY25 margin and EPS growth driven by ERP shipments, with FY26 headwinds as benefits reverse.CLX
Q4 20258 Jul 2026 - ERP stabilization, innovation, and GOJO integration drive growth amid leadership transition.CLX
23rd annual dbAccess Global Consumer Conference3 Jun 2026 - ERP completion, innovation, and GOJO acquisition drive growth and margin expansion plans.CLX
Citi’s 2026 Global Consumer & Retail Conference 20269 Mar 2026 - Digital and portfolio advances, plus GOJO acquisition, drive growth and health & hygiene scale.CLX
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - Margin expansion and portfolio reshaping drive FY24 results and FY25 outlook.CLX
Q4 20242 Feb 2026